Guardant Health has announced that its Guardant Reveal test, a blood-based assay for minimal residual disease (MRD) detection, is now covered by Medicare for monitoring colorectal cancer (CRC) recurrence following curative intent treatment. Unlike traditional tumor-informed MRD tests, Guardant Reveal uses a tissue-free approach, leveraging circulating tumor DNA (ctDNA) via epigenomic analysis. This method addresses the challenge faced by over 12 million U.S. cancer patients lacking available tissue specimens for testing. By integrating this non-invasive test with standard care such as CT scans and CEA testing, clinicians can detect molecular recurrence earlier, guiding therapeutic decisions and improving outcomes.
Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients (Business Wire)
0